KRAS and colorectal carcinoma: This study ultimately showed that the co-inhibition of CDK4/6 and MEK caused a therapeutic response in both KRAS-mutated and BRAF-mutated CRC while demonstrating limited activity against KRAS WT and normal colon cells [82].